Efficacy and safety of duloxetine in patients with chronic low back pain

This was a randomized, double-blind, placebo-controlled clinical trial. To assess the efficacy and safety of duloxetine in the treatment of chronic low back pain (CLBP). Imbalance of serotonin and norepinephrine within modulatory pain pathways has been implicated in the development and maintenance o...

Full description

Saved in:
Bibliographic Details
Published in:Spine (Philadelphia, Pa. 1976) Pa. 1976), 2010-06, Vol.35 (13), p.E578-E585
Main Authors: Skljarevski, Vladimir, Desaiah, Durisala, Liu-Seifert, Hong, Zhang, Qi, Chappell, Amy S, Detke, Michael J, Iyengar, Smriti, Atkinson, Joseph H, Backonja, Miroslav
Format: Article
Language:English
Subjects:
Adult
Aged
Chronic Disease
Diarrhea - chemically induced
Double-Blind Method
Duloxetine Hydrochloride
Fatigue - chemically induced
Female
Humans
Low Back Pain - drug therapy
Low Back Pain - physiopathology
Male
Middle Aged
Nausea - chemically induced
Pain Measurement
Serotonin Uptake Inhibitors - adverse effects
Serotonin Uptake Inhibitors - therapeutic use
Thiophenes - adverse effects
Thiophenes - therapeutic use
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This was a randomized, double-blind, placebo-controlled clinical trial. To assess the efficacy and safety of duloxetine in the treatment of chronic low back pain (CLBP). Imbalance of serotonin and norepinephrine within modulatory pain pathways has been implicated in the development and maintenance of chronic pain. Duloxetine, a selective reuptake inhibitor of serotonin and norepinephrine, has demonstrated clinical efficacy in 3 distinct chronic pain conditions: diabetic peripheral neuropathic pain, fibromyalgia, and chronic pain because of osteoarthritis. In this randomized double-blind trial, adult nondepressed patients with a non-neuropathic CLBP and a weekly mean of the 24-hour average pain score>or=4 at baseline (0-10 scale) were treated with either duloxetine or placebo for 13 weeks. The dose of duloxetine during first 7 weeks was 60 mg once daily. At week 7, patients reporting
ISSN:0362-2436
1528-1159
DOI:10.1097/BRS.0b013e3181d3cef6